info:eu-repo/semantics/article
Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer
Fecha
2017-03Registro en:
Gentilini, Lucas Daniel; Jaworski, Felipe Martín; Tiraboschi, Carolina Daniela; Gonzalez Perez, Ignacio; Kotler, Monica Lidia; et al.; Stable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer; Impact Journals LLC; Oncotarget; 8; 27; 3-2017; 44654-44668
1949-2553
CONICET Digital
CONICET
Autor
Gentilini, Lucas Daniel
Jaworski, Felipe Martín
Tiraboschi, Carolina Daniela
Gonzalez Perez, Ignacio
Kotler, Monica Lidia
Chauchereau, Anne
Laderach, Diego Jose
Compagno, Daniel Georges
Resumen
Two decades ago, Galectin-8 was described as a prostate carcinoma biomarker since it is only expressed in the neoplastic prostate, but not in the healthy tissue. To date, no biological function has been attributed to Galectin-8 that could explain this differential expression. In this study we silenced Galectin-8 in two human prostate cancer cell lines, PC3 and IGR-CaP1, and designed a pre-clinical experimental model that allows monitoring the pathology from its early steps to the long-term metastatic stages. We show for the first time that the natural and conserved expression of Gal-8 in tumour cells is responsible for the metastatic evolution of prostate cancer. In fact, Gal-8 controls the rearrangement of the cytoskeleton and E-Cadherin expression, with a major impact on anoikis and homotypic aggregation of tumour cells, both being essential processes for the survival of circulating tumour cells during metastasis. While localized prostate cancer can be cured, metastatic and advanced disease remains a significant therapeutic challenge, urging for the identification of prognostic markers of the metastatic process. Collectively, our results highlight Galectin-8 as a potential target for anti-metastatic therapy against prostate cancer.